Article Text

Download PDFPDF

4CPS-260 Persistence and safety of calcitonin gene-related peptide inhibitors in chronic migraine
  1. L Carrasco Piernavieja,
  2. I Salvador Llana,
  3. B Sanchez Pascual,
  4. E Zhan Zhou,
  5. M Leal Alvarez,
  6. AM Duro Martinez,
  7. P Sanmartin Fenollera,
  8. M Perez Encinas
  1. Hospital Universitario Fundación Alcorcón, Hospital Pharmacy, Alcorcón, Spain


Background and importance Monoclonal antibodies against calcitonin gene-related peptide or its receptor (mAb-CGRP) offer improvements over available drugs in migraine prophylaxis. Safety and persistence are essential to achieve disease management goals.

Aim and objectives To assess the persistence and safety of mAb-CGRP in patients with chronic migraine in clinical practice.

Material and methods In this observational retrospective single-centre study, all patients with chronic migraine treated for at least 1 month with mAb-CGRP between December 2019 and September 2021 were included.

The primary outcome was first- and second-line persistence (patients treated less than 3 months were excluded), which was analysed using Kaplan–Meier survival curves and the log-rank test for comparison. Secondary outcomes were adverse effect rate and reasons for discontinuation.

Variables collected were age, sex, number of migraines/month, previous treatments, mAb-CGRP type, start and discontinuation date, reasons for discontinuation, mAb-CGRP switching and adverse effects (AEs).

Results Ninety-four patients with median migraines/month of 14 (IQR 10–20) were included; median age: 50 years (IQR 44–58); 84.04% women. All patients received at least three previous preventive treatments: botulinum toxin (100%), tricyclic antidepressants (90.43%), neuromodulators (88.30%), calcium-channel blockers (64.89%), beta-blockers (59.57%) and others (21.28%).

Abstract 4CPS-260 Table 1

The main reason for discontinuation was ineffectiveness (80.77%). Other reasons were treatment ending, pregnancy, loss of follow-up and patient’s decision.

Median overall persistence for first- and second-line treatment was 13.6 months (95% CI 11.01 to 16.19) and 9.0 months (95% CI 4.61 to 13.39), respectively. Median persistence in first line for erenumab was 13.4 months (95% CI 10.94 to 15.86), for galcanezumab 15.3 months (95% CI 11.81 to 18.79) and fremanezumab was not reached (p>0.05). The 12-month overall persistence rates for first and second line were 67.04% and 52.10%, respectively (p>0.05).

AEs appeared in 21 patients: constipation (8.51%), injection-related headache (5.32%), fatigue/arthralgia (4.26%), injection-site reaction (4.26%), vertigo (2.13%) and menstrual disorders (2.13%). Other AEs were weight loss, insomnia and alopecia. One patient discontinued due to hypersensitivity.

Conclusion and relevance First- and second-line treatment with mAb-CGRP showed similar levels of persistence. First-line erenumab and galcanezumab also demonstrated the same results. The frequency of AEs is lower than reported in clinical trials, so we can conclude that mAb-CGRPs are safe drugs.

Conflict of interest No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.